Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers [Phase 2]
Phase II trial of XmAb20717 for advanced rare cancers has been suspended, with eligibility including microsatellite instability-high cancers…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy for metastatic, poorly differentiated Grade 3 neuroendocrine carcinoma of gastroenteropancr…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
This Clinical Trial Update discusses patient journeys and treatment outcomes for neuroendocrine carcinomas in Latin America; the trial NCT07…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]
Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors [Phase 1, Phase 2]
An ongoing Phase 1/2 study investigates systemic VSV-IFNβ-NIS in combination with checkpoint inhibitors for select solid tumors. The trial i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies [Phase 1]
Ongoing Phase 1 safety/efficacy trial of CID-078 in patients with advanced/metastatic solid tumors; study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial evaluating the combination of sintilimab with surufatinib and temozolomide for advanced neuroendocrine carcinomas is not yet r…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer [Phase 2]
Phase 2 study assessing bevacizumab in combination with FOLFIRI as second-line therapy for advanced, inoperable poorly differentiated neuroe…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas [Phase 1]
Phase 1 clinical trial update for NP-101 (TQ Formula) in combination with nivolumab and ipilimumab for advanced or metastatic extra-pulmonar…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) [NA]
A completed clinical trial evaluating Gallium-68 DOTATATE PET-CT for diagnosing neuroendocrine tumors (NETs).
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET [Phase 2]
A Phase 2 trial of iadademstat in combination with paclitaxel for relapsed/refractory small-cell lung cancer and extrapulmonary high-grade n…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas [Phase 2]
Phase 2 neoadjuvant chemotherapy trial in patients with localized digestive neuroendocrine carcinomas, currently recruiting, assessing disea…
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial [Phase 2]
Phase 2 clinical trial evaluating NALIRIFOX as second-line chemotherapy for extrapulmonary high-grade neuroendocrine neoplasms; the study is…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma [Phase 4]
This clinical trial update describes a Phase 4 study of liposomal irinotecan for advanced neuroendocrine carcinoma that is not yet recruitin…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
This clinical trial update describes the REBORN study, which aims to identify biomarkers for diagnosing neuroendocrine tumors and assessing …
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating nab-paclitaxel in combination with bevacizumab for metastatic extrapulmonary neuroendocrine carcinoma has complet…
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) [Phase 2]
A Phase 2 clinical trial is evaluating a triple combination of sintilimab, IBI310, and surufatinib for high-grade neuroendocrine tumors and …
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7616789 in advan…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas [Phase 2]
A Phase 2 trial comparing CAPTEM (capecitabine + temozolomide) versus FOLFIRI as second-line therapy for neuroendocrine carcinoma was termin…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer [Phase 1]
Phase 1 study evaluating adding BAY 1895344 to standard chemotherapy for advanced solid tumors, focusing on small cell lung cancer, poorly d…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Clinical Application of the J-PET Scanner Prototype
Clinical trial update announcing recruitment for a prototype J-PET scanner. The study targets imaging in prostate cancer, benign prostatic h…
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) [Phase 2]
TAURUS is a Phase 2 clinical trial evaluating tarlatamab for advanced extrapulmonary small cell carcinoma and neuroendocrine carcinoma, with…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating second-line therapy for progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma has completed.
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. [Phase 1, Phase 2]
A dose-escalation and expansion Phase 1/2 trial of ZG006 in neuroendocrine carcinoma and advanced small cell lung cancer is currently recrui…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours [Phase 2]
Open-label Phase 2 registry study evaluating Lu-DOTA-TATE in patients with somatostatin receptor–positive neuroendocrine tumors.